Event in Progress:
Research Tree provides access to ongoing research coverage, media content and regulatory news on Attana Ab. We currently have 0 research reports from 0 professional analysts.
2021 was a tough year which saw the non-repeat of highly profitable hand sanitiser sales, almost no Chinese sales and the impact of input/cost inflation. However, it successfully integrated 2 acquisitions, which enhance the portfolio and earnings quality, and locked in the planned synergies. With new distribution agreements (inc to China), and mitigations in place to claw back lost margin, VLG looks set to return to profitable growth. The platform is highly scalable and trades on just 5x EV/EBIT
Companies: Venture Life Group Plc
MRx-4DP0004 is 4D Pharma’s oral, immunomodulatory, single strain Live Biotherapeutic product (LBP). The safety portion of this Phase 1/2 (Part A) met the primary endpoint of safety and tolerability, with five secondary endpoints qualitatively improved over the placebo arm. The data is being presented in poster session at the ATS meeting May 15-18, 2022.
Companies: 4d Pharma PLC
4D Pharma is a pharmaceutical company developing Live Biotherapeutic Products (LBPs), a novel class of drug derived from the human gut microbiome. This differentiated approach focuses on leveraging the interactions of LBPs with host biology, underpinned by a proprietary MicroRx® platform. This has generated a strong clinical and preclinical pipeline of single strain LBPs targeting major diseases across multiple therapeutic area. A well flagged cash requirement overshadows the stock but the exper
Companies: SDI Group plc
Companies: Futura Medical plc
Companies: Kromek Group Plc (KMK:LON)Synairgen plc (SNG:LON)
Weekly round-up of AIM-listed healthcare news. Venture Life Group, GENinCode, Kromek, Alliance Pharma, Polarean Imaging, Benchmark Holdings, Ondine Biomedical, Verici Dx, Faron Pharmaceuticals, Avacta Group, Abingdon Health, Open Orphan, Belluscura, Hutchmed (China), Oxford Biodynamics
Companies: ANIC RUA CREO GENI HEIQ IHC IXI IUG OPTI SBTX VAL VLG
Yourgene’s Capital Markets Day on 26/4 provided a strong illustration of the significant strategic progress the group has made in recent years. The pandemic was both a blessing and a curse for YGEN, delaying some opportunities, but catalysing others and leaving the group in a stronger net position than where it started. The building blocks are now in place and, as healthcare markets normalise globally, we believe Yourgene is poised for a period of extended growth, with multiple opportunities to
Companies: Yourgene Health Plc
Dish of the day Joiners: No Joiners Today. Leavers: No Leavers Today. What’s cooking in the IPO kitchen? Lekoil, the oil and gas exploration and production Company with a focus on Nigeria and West Africa intends to join the AQSE Growth Market. The Company was previously listed on AIM (LEK.L), however, Ordinary Shares have been suspended from trading on AIM since October 2021. Due 18th May 2022. EnSilica, intends to join AIM. EnSilica is a designer and supplier of mixed signal Application Specifi
Companies: EEE FARN FCAP HZM JLP NSCI SRE
A positive AGM update confirms strong revenue growth has continued YTD and further margin improvement means management again expect EBITDA to be materially ahead of expectations. The business model is now settled, with additional distributors appointed in the US which should help drive further penetration into the Primary Care market there. China revenues were strong and with no sign yet of any slowdown, despite being cognisant of renewed lockdowns there. Gross margins have remained robust on po
Companies: Circassia Group PLC
Venture Life Group has reported its results for FY21A, with revenues and adjusted EBITDA coming in ahead of our forecasts. Revenues, supported by two acquisitions, grew 9% to £32.8m with the acquisitions more than offsetting lost FY20A COVID-related sales and significantly reduced shipments to China. The gross margin was also affected by these factors, though also supported by higher margin acquisitions. Adjusted EBITDA grew 8%. Management have provided a positive outlook for FY22E, based on tra
Companies: RUA Life Sciences Plc
Omega Diagnostics has raised £2.0m, with up to £2.0m possible via an Open Offer to provide a bridge to the sale of the CD4 business and enable it to focus on the growth opportunities within its core business, Health & Nutrition. Having sold its Alva site in March for £1m, with a transitionary agreement put in place with Accubio until December 2022 to ensure the continued production of CD4 lateral flow tests, Omega has elected to sell the CD4 business, which would cost c.£1.5m to relocate to Ely
Companies: Omega Diagnostics Group PLC
Dish of the day Joiners: Lekoil, the oil and gas exploration and production Company with a focus on Nigeria and West Africa has joined the Access Segment of the AQSE Growth Market. The Company was previously listed on AIM (LEK.L), however, Ordinary Shares have been suspended from trading on AIM since October 2021. Leavers: No Leavers Today. What’s cooking in the IPO kitchen? Psych Capital PLC, intends to list on the AQSE Growth Market. Psych operates the Psych Platform (a business-to-business ne
Companies: CZA AXL AEE CORA D4T4 EKF ORPH PWM PPH SYM
FY21 results were well-trailed and contain no surprises. The company continues to execute in line or ahead of plan and, following a £10m fundraise post-period end, is funded through a number of key inflection points. Investors can look forward to a number of these in the near term, including commercial launch and first revenues from first product Tuteva later this year. Rolling forward our risk-adjusted DCF results in a further increase in our TP to 76p (from 65p). we reiterate our Buy recommend
Companies: Verici Dx Plc
Share: